{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:59:13Z","timestamp":1760385553595},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.diagmicrobio.2017.03.008","type":"journal-article","created":{"date-parts":[[2017,4,2]],"date-time":"2017-04-02T10:46:26Z","timestamp":1491129986000},"page":"259-263","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest\u00ae MIC values of 1.5 mg\/L: A pilot study"],"prefix":"10.1016","volume":"88","author":[{"given":"D.M.","family":"Martirosov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Bidell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.P.","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0005","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3201\/eid\/1706.101037","article-title":"High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia","volume":"17","author":"Aguado","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2017.03.008_bb0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC 24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0015","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cid\/ciu183","article-title":"Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis","volume":"58","author":"Cervera","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0020","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-ninth edition: Approved standard. M07\u2013A9 ed","author":"CLSI","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0025","series-title":"ADAPT 5 User's guide: Pharmacokinetic\/Pharmacodynamic systems analysis software","author":"D'Argenio","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0030","series-title":"45th annual meeting of the Infectious Diseases Society of America, San Diego, CA","article-title":"Vancomycin dose recommendations for hospital-, ventilator- or health care-associated pneumonia and the attainment of vancomycin trough concentrations of 15\u201320 mg\/L: Cognitive dissonance","author":"Drusano","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0035","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","author":"Van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0045","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0050","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/1469-0691.12168","article-title":"Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia","volume":"19","author":"Holmes","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2017.03.008_bb0055","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1128\/JCM.01320-14","article-title":"Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates","volume":"52","author":"Holmes","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/529190","article-title":"Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia","volume":"46","author":"Jenkins","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2017.03.008_bb0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"15","key":"10.1016\/j.diagmicrobio.2017.03.008_bb0070","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1001\/jama.2014.6364","article-title":"Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis","volume":"312","author":"Kalil","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0080","first-page":"1","article-title":"Vancomycin exposure in patients with MRSA bloodstream infections: how much is enough?","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0085","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0090","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.03.008_bb0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/519283","article-title":"A systematic review of the methods to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients","volume":"45","author":"McGregor","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0105","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/aje\/kwg074","article-title":"Estimating the relative risk in cohort studies and clinical trials of common outcomes","volume":"157","author":"McNutt","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1086\/342384","article-title":"Has antifungal susceptibility testing come of Age?","volume":"35","author":"Rex","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkl030","article-title":"Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia","volume":"57","author":"Sakoulas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0135","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1086\/665731","article-title":"The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Stevens","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2017.03.008_bb0140","series-title":"Recursive partitioning in the health Sciences","author":"Zhang","year":"1999"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317300846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T21:55:11Z","timestamp":1535925311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317300846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0732889317300846"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.008","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest\u00ae MIC values of 1.5mg\/L: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}